Sunesis Pharmaceuticals (SNSS) Misses Q4 EPS by 1c

Sunesis Pharmaceuticals (NASDAQ: SNSS) reported Q4 EPS of ($0.15), $0.01 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $670 thousand versus the consensus estimate of $700 thousand.

For earnings history and earnings-related data on Sunesis Pharmaceuticals (SNSS) click here.

You May Also Be Interested In

• Rivian reports record Q3 deliveries, beats estimates, shares rise
• Goldman Sachs Downgrades Carl Zeiss Meditec AG (AFX:GR) (CZMWY) to Sell
• RBC Capital Upgrades Brunello Cucinelli SpA (BC:IM) (BCUCF) to Outperform